Everolimus and Exemestane Combination Prolonged PFS for Advanced Postmenopausal Breast Cancer Patients

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

For women with advanced breast cancer resistant to hormonal therapy, combining everolimus and exemestane improves progression-free survival (PFS) by nearly 7 months compared with exemestane alone, according to phase 3 trial results reported at the European Multi - disciplinary Cancer Conference. The Breast Cancer Trials of Oral Everolimus (BOLERO) randomized 724 patients in 24 countries who had been treated previously with letrozole or anastrozole. Previous therapy also included tamoxifen, fulvestrant, and chemotherapy. The trial was stopped early when interim analysis revealed that patients receiving the combination regimen did not experience tumor progression for nearly 11 months, whereas patients receiving exemestane alone progress after approximately 4 months.

Related Items
Pembrolizumab Approved for Patients with Head and Neck Cancer
In the News: Oncology - August 2016 published on August 10, 2016 in In the News
Beth Faiman Nominated for Leukemia & Lymphoma Society Woman of the Year
TON March 2016 Vol 9 No 2 published on March 22, 2016 in In the News
CYP2D6 Genotyping Fails to Predict Effectiveness of Tamoxifen
Alice Goodman
TOP - April 2012, Vol 5, No 2 published on April 27, 2012 in In the News
"Chemo Brain" Can Persist for 2 Decades
TOP - April 2012, Vol 5, No 2 published on April 27, 2012 in In the News
Chronic Kidney Disease and Risk of Kidney Cancer
TON - MARCH 2012 VOL 5, NO 2 published on April 27, 2012 in In the News
CYP2D6 Genotyping Fails to Predict Effectiveness of Tamoxifen
Alice Goodman
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
“Chemo Brain” Can Persist for 2 Decades
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
GIST Outside GI Tract Has Poor Prognosis
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
Bone Biomarker Identified for Metastatic Prostate Cancer
Alice Goodman
TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Protocol-Ineligible Patients With Metastatic Renal Cell Carcinoma Fare Worse Than Those Eligible for Clinical Trials
TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Last modified: May 21, 2015